In patients with invasive cervical cancer, the most common sentinel node locations are external iliac, obturator and parametrium, according to a study published in the December issue of the American Journal of Obstetrics and Gynecology.
In patients with invasive cervical cancer, the most common sentinel node locations are external iliac, obturator and parametrium, according to a study published in the December issue of the American Journal of Obstetrics and Gynecology.
Arnim A. Bader, MD, of the Medical University of Graz in Graz, Austria, and colleagues reviewed 619 patients with invasive cervical cancer who were treated by radical abdominal hysterectomy and systematic pelvic or pelvic and paraaortic lymphadenectomy, including 61 who had one positive lymph node and 59 who had two positive lymph nodes.
The researchers found solitary metastases were most often located in the external iliac and obturator regions and the parametrium (43%, 26%, and 21%, respectively). In patients with two positive nodes, they found the most common combinations were one parametrial and one pelvic node (32%), two ipsilateral positive nodes (31%), or one positive lymph node on each side of the pelvis (27%).
"Sentinel node identification is a convincing concept that will increasingly gain acceptance in cervical cancer," the authors conclude. "Our data of sentinel node localization and investigation of lymphatic spread beyond sentinel nodes may help refine the sentinel technique in cervical cancer."
Bader AA, Winter R, Haas J, et al. Where to look for the sentinel lymph node in cervical cancer. Am J Obstet Gynecol. 2007;197:678.e1-678.e7.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More